Afghanistan’s pharmaceutical market has entered a new phase over the past year. The country’s long-standing dependence on Pakistan is gradually changing under the weight of political disputes, military clashes, closed trade routes, and the Taliban’s decision to halt pharmaceutical imports from Pakistan. For years, Afghanistan sourced a significant share of its medicine and medical equipment from Pakistan. India is now better placed than any other alternative to fill part of the gap that has opened in the Afghan market and to become one of the country’s major suppliers of medicine and medical equipment. Russia has also entered the field alongside India as an emerging option. This development is not merely a shift between suppliers. It may signal a broader transformation in the structure of Afghanistan’s pharmaceutical supply, one in which India could take on a more central role, and Afghanistan could move toward reducing its reliance on a single source and diversifying the supply of its essential goods.
A significant part of Afghanistan’s pharmaceutical market has long depended on Pakistani products. Geographic proximity, relatively short land routes, and a broad network of traders and pharmaceutical companies made Pakistan one of the main suppliers of medicine to Afghanistan. However, the closure of border crossings and the escalating disputes between the Taliban and Pakistan have turned this dependence into a weakness for the Afghan market. The Taliban have justified the formal halt on pharmaceutical imports from Pakistan with reasons such as concerns about drug quality and the need to identify new sources. In practice, however, it has created a gap in the market that Afghanistan will struggle to fill. The situation has given India a new opportunity to expand its presence in Afghanistan’s pharmaceutical sector. New Delhi not only has extensive drug manufacturing capacity but also holds an important position globally in the production of generic medicines, vaccines, medical equipment, and healthcare-related technologies. From this perspective, India is not merely a replacement supplier for Afghanistan but could become an important partner in building a more stable pharmaceutical supply chain.
In recent months, contacts and talks between Taliban health officials, Indian institutions, and Indian pharmaceutical companies have also created new opportunities for expanding cooperation. A number of Afghanistan-based companies are seeking to expand their trade relations by drawing on India’s production capacity and to sign new contracts with Indian pharmaceutical firms. This trend could gradually strengthen India’s position in Afghanistan’s pharmaceutical market and offset part of the gap caused by the decline in imports from Pakistan.
Still, the main question is whether India has managed to fully take Pakistan’s place in the Afghan pharmaceutical market. Under current conditions, the answer is no. India’s main challenge is not a shortage of production capacity but geography and the routes by which goods are transported. Afghanistan and India do not share a border, and a considerable portion of India’s trade with Afghanistan depends on routes that pass through Pakistan or on alternatives such as Iran’s Chabahar Port. This raises the cost and time of transporting medicine and makes regular, affordable access to the Afghan market more difficult.
Chabahar Port could play an important role in this regard. However, the capacity of this route and the cost of using it are still not comparable to the extensive, well-established land transport network through Pakistan. These limitations show that, despite their efforts to increase imports from India, Afghanistan-based companies cannot fully replace Pakistan’s position in the short term.
As a result, although Indian medicines may have advantages in terms of quality and manufacturing standards, transport costs could make them more expensive than Pakistani products for consumers in Afghanistan. This is where one of the contradictions of Afghanistan’s pharmaceutical market becomes apparent: the formal ban on imports from Pakistan does not necessarily mean the end of Pakistani medicines in Afghanistan. Reports have been published indicating that Pakistani medicines enter the country through informal routes, an activity said in some cases to take place with the cooperation of some Taliban border forces. Lower prices and easier access remain the main advantages of these products, while medicines imported from India face additional transport and customs costs.
Therefore, the competition between Indian medicines, which may be of higher quality, and cheaper Pakistani products goes beyond trade and is directly tied to public health and market oversight. Reports have also been published about the cooperation or collusion of certain individuals with smuggling networks along the Afghanistan-Pakistan border. However, the more important issue is the continued operation of the informal market. The persistence of this market shows that an administrative ban, without effective border control and the creation of legal, competitive channels for supplying medicine, cannot on its own end Afghanistan’s long-standing dependence on Pakistan’s pharmaceutical market.
In these circumstances, Russia’s entry into Afghanistan’s pharmaceutical market has created another option alongside India. The meeting between Noor Jalal Jalali, the Taliban’s Minister of Public Health, and Mikhail Murashko, Russia’s Minister of Health, along with discussions on the supply of medicine, vaccines, medical equipment, and technology transfer, indicates that the Taliban are seeking to broaden the range of their partners in the health sector.
Even so, India remains in a stronger position owing to its extensive drug manufacturing capacity and relatively established trade relations. Russia, by contrast, can act as a complementary partner and help diversify the sources of Afghanistan’s medicine supply. Nevertheless, it is also unlikely that Russia could fully take Pakistan’s place in the short term. Geographic distance, transport costs, trade restrictions, and the absence of an extensive distribution network inside Afghanistan are significant obstacles to Russia becoming the country’s main supplier of medicine. Cooperation with Russia will therefore most likely serve as a complementary track within the Taliban’s broader strategy of diversifying supply sources, rather than as an immediate replacement for Pakistan or India.
Among these options, India holds a special position. On one hand, the country has extensive drug manufacturing capacity and considerable export experience. On the other hand, through Chabahar Port, it can offer Afghanistan a route of access that does not depend on Pakistan. In addition, India’s long-standing historical and cultural ties with the people of Afghanistan, along with its record of humanitarian assistance, are a valuable asset that could take health cooperation beyond the framework of purely commercial relations.
If this capacity is accompanied by greater investment in transit infrastructure, trade facilitation, and stronger cooperation between Afghanistan-based and Indian companies, India could become Afghanistan’s most important foreign partner in the field of medicine and medical equipment.
Even so, reaching such a position depends above all on preventing the entry of medicine through informal border routes. Given the possible economic interests of some actors in this informal trade, the Taliban may have limited incentive to adopt effective measures to curb it. In such circumstances, even India’s extensive pharmaceutical capacity cannot, on its own, restore order and stability to Afghanistan’s pharmaceutical market.
Therefore, Afghanistan’s challenge is not simply choosing which country to source its needed medicines from. The more important matter is building a stable, high-quality, affordable, and accessible system for supplying medicine. Pakistan continues to maintain its presence through the informal market; Russia has emerged as a potential newcomer, and India, relying on its manufacturing capacity and expanding trade relations, is better placed than the other options to become one of Afghanistan’s major pharmaceutical partners.
Ultimately, the shift in Afghanistan’s medicine supply from Pakistan toward India and Russia is part of the Taliban’s broader effort to reduce dependence on a single country and a single trade route. However, the success of this process depends on curbing smuggling from Pakistan, strengthening alternative transit routes, and creating fair competition among suppliers. Undoubtedly, India has the capacity to secure an important position in Afghanistan’s pharmaceutical market. Otherwise, the market may remain caught between costly formal imports on one side and cheaper informal supply on the other, a situation in which the public health of the people will ultimately pay the highest price.
You can read the Persian version of this analysis article here:
دارو و دیپلماسی: تغییر مسیر افغانستان از پاکستان به هند و روسیه
The post Medicine and Diplomacy: Afghanistan Turns from Pakistan to India and Russia appeared first on Hasht-e Subh.